Global News

Third Rock launches MyoKardia with $38M for genetic heart disease

Friday, September 21, 2012 10:51 AM

Third Rock Ventures, a venture capital firm of Boston, Mass., has formed new company MyoKardia with a $38 million Series A financing. MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease.

More... »

Boston Scientific to acquire BridgePoint Medical

Thursday, September 20, 2012 07:30 AM

Boston Scientific, a global developer, manufacturer and marketer of medical devices, agreed to acquire BridgePoint Medical, a privately held company based in Minneapolis, Minn. The transaction is expected to close in the fourth quarter of 2012 subject to customary closing conditions.

More... »

AMRI forms strategic contract with Knopp Biosciences

Wednesday, September 19, 2012 03:18 PM

AMRI, a global contract research and manufacturing organization, has entered into a new strategic agreement with Knopp Biosciences, a Pittsburgh-based drug discovery and development company focused on breakthrough treatments for unmet needs in neurological disorders.  

More... »

Baxter, Onconova form European licensing agreement for anti-cancer compound rigosertib

Wednesday, September 19, 2012 03:11 PM

Baxter International, a developer, manufacturer and marketer of medical products, and Onconova Therapeutics, a discoverer and developer of novel small molecule therapeutics, have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound currently in a phase III study for the treatment of a group of rare hematologic malignancies called myelodysplastic syndromes (MDS) and in a phase II/III study for pancreatic cancer.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

Quintiles, Sinclair ink 10-year partnership to commercialize portfolio in Mexico

Wednesday, September 19, 2012 11:37 AM

Quintiles, a fully integrated biopharmaceutical services company, and Sinclair IS Pharma, a topicals and supportive care specialist, have signed a 10-year collaboration and licensing agreement for Quintiles (Rowfarma Mexico) to commercialize Sinclair’s portfolio of dermo-cosmetic products and medical devices in Mexico.

More... »

Complete Genomics, BGI-Shenzhen ink merger

Tuesday, September 18, 2012 07:00 AM

Complete Genomics, a Mountain View, Calif.-based provider of whole human genomic sequencing, and BGI-Shenzhen, an international genomics company based in Shenzhen, China, have entered into a definitive merger agreement.

More... »

Bayer elects Werner Wenning as chairman

Monday, September 17, 2012 03:08 PM

Bayer’s  supervisory board has elected Werner Wenning as its chairman, who had already been elected by the Annual Stockholders' Meeting of Bayer in April 27, 2012, to become a member of the supervisory board effective October 1.

More... »

Danaher to acquire Iris International for $19.50 per share

Monday, September 17, 2012 02:52 PM

Danaher, a science and technology company, has agreed to acquire Iris International, a manufacturer of automated in vitro diagnostics systems and provider of personalized medicine solutions, for $19.50 per share in cash, representing an approximate 45% premium over the closing price of Iris's common stock on September 14, 2012.

More... »

Life Technologies, BMS to partner on diagnostics development

Monday, September 17, 2012 01:17 PM

Life Technologies, a global biotech, has entered into a master development agreement with Bristol-Myers Squibb for current and future companion diagnostics projects.

More... »